incretin mimetics glp 1 agonists GLP-1 Analogues Structures of formulations of GLP-1

doi:10.1056/NEJMoa2301972 206

GLP-1 has a direct effect on adipose tissue

Physiology or pharmacology

The decades of research on CR suggest that the reduction in cancer incidence in CR is facilitated by the reduction in glucose, insulin, and IGF-1 levels, which would otherwise stimulate cell growth and proliferation, and the reduction in oxidative stress and inflammation (49, 50)

AMG133 (subcutaneous, every 4 weeks) is a monoclonal antibody that was designed to antagonise the GIP receptor and is also linked to two modified GLP-1 peptides that activate the GLP-1 receptor [58]

Its widely known that those conditions are driven by complex biological determinants, including genes, as well as environmental factors